drugset / Trial / NCT04472494

Study of Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise

NCT04472494

Phase 2 Terminated 61 enrolled Bristol-Myers Squibb
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of intravenous abatacept administered to hospitalized COVID-19 participants with respiratory compromise.

Timeline

Start
2020-10-14
Primary completion
2021-08-12
Completion
2021-09-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Abatacept Other / unclassified Intravenous

Indications